ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 232 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $214,777 | -17.2% | 10,306 | -4.8% | 0.15% | -10.1% |
| Q2 2023 | $259,354 | +25.2% | 10,829 | -1.6% | 0.17% | +23.4% |
| Q1 2023 | $207,170 | +18.2% | 11,008 | 0.0% | 0.14% | +11.4% |
| Q4 2022 | $175,247 | -2.6% | 11,008 | 0.0% | 0.12% | -10.9% |
| Q3 2022 | $180,000 | +16.1% | 11,008 | 0.0% | 0.14% | +21.1% |
| Q2 2022 | $155,000 | -52.7% | 11,008 | -18.6% | 0.11% | -43.8% |
| Q1 2022 | $328,000 | +20.1% | 13,516 | +15.8% | 0.20% | +18.0% |
| Q4 2021 | $273,000 | +34.5% | 11,672 | -4.1% | 0.17% | +22.0% |
| Q3 2021 | $203,000 | -31.2% | 12,172 | 0.0% | 0.14% | -9.6% |
| Q2 2021 | $295,000 | -6.1% | 12,172 | 0.0% | 0.16% | -12.8% |
| Q1 2021 | $314,000 | -51.8% | 12,172 | 0.0% | 0.18% | -57.1% |
| Q4 2020 | $651,000 | -28.1% | 12,172 | -44.5% | 0.42% | -25.4% |
| Q3 2020 | $905,000 | – | 21,921 | – | 0.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |